Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.

Pemetrexed is one of the first-line chemotherapeutic agents for non-squamous non-small cell lung cancer (NSCLC). Since 2017, intrathecal pemetrexed has shown good efficacy for patients with leptomeningeal metastases from NSCLC. It has been recommended as the preferred drug for intrathecal chemotherapy by the Chinese Society of Clinical Oncology (CSCO) guidelines. Tyrosine kinase inhibitors (TKIs) play a promising role in treating non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations. An international multi-center clinical study published in 2019 confirmed t

Trial Details

NCT ID
NCT06296745
Phase
PHASE2
Sponsor
Guangzhou Medical University
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Pemetrexed
Locations (sample)
  • Huizhou, Guangdong, China|23.11147,114.41523

Key Eligibility Criteria

  • Male or female aged between 18 and 75 years.
  • Histologically or cytologically confirmed diagnosis of NSCLC with single activating EGFR mutations (L858R or Exon19Del).
  • Confirmed diagnosis of leptomeningeal metastasis according to ESMO/ EANO guidelines.
  • Progression after previous double doses of third-generation TKIs such as Osimertinib.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →